Process research and scale-up of a commercialisable route to maraviroc (UK-427,857), a CCR-5 receptor antagonist

…, SJ Haycock-Lewandowski, J Long…

Index: Ahman, Jens; Birch, Melissa; Haycock-Lewandowski, Sarah J.; Long, James; Wilder, Alexander Organic Process Research and Development, 2008 , vol. 12, # 6 p. 1104 - 1113

Full Text: HTML

Citation Number: 23

Abstract

A six-step synthetic route to the CCR-5 receptor antagonist, Maraviroc (UK-427,857)(1) has been developed and demonstrated at scale in a pilot plant. The route has supported four Pilot-Plant campaigns and has produced multikilogram quantities of 1. Continued development of the synthetic route has resulted in a robust process with improved throughput compared to that of the original synthesis (Haycock-Lewandowski, SJ; Mawby, ...

Related Articles:

Affinity and avidity in antibody-based tumor targeting

[Asano, Shigehiro; Gavrilyuk, Julia; Burton, Dennis R.; Barbas, Carlos F. ACS Medicinal Chemistry Letters, 2014 , vol. 5, # 2 p. 133 - 137]

Affinity and avidity in antibody-based tumor targeting

[Asano, Shigehiro; Gavrilyuk, Julia; Burton, Dennis R.; Barbas, Carlos F. ACS Medicinal Chemistry Letters, 2014 , vol. 5, # 2 p. 133 - 137]

Affinity and avidity in antibody-based tumor targeting

[Asano, Shigehiro; Gavrilyuk, Julia; Burton, Dennis R.; Barbas, Carlos F. ACS Medicinal Chemistry Letters, 2014 , vol. 5, # 2 p. 133 - 137]

Affinity and avidity in antibody-based tumor targeting

[Asano, Shigehiro; Gavrilyuk, Julia; Burton, Dennis R.; Barbas, Carlos F. ACS Medicinal Chemistry Letters, 2014 , vol. 5, # 2 p. 133 - 137]

Affinity and avidity in antibody-based tumor targeting

[Asano, Shigehiro; Gavrilyuk, Julia; Burton, Dennis R.; Barbas, Carlos F. ACS Medicinal Chemistry Letters, 2014 , vol. 5, # 2 p. 133 - 137]

More Articles...